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SB203580The P2X7 receptor is a calcium permeable cationic channel activated by extracellular ATP, playing a role
in chronic pain, osteoporosis and arthritis. A number of potential lead compounds are inactive against
the rat isoform, despite good activity against the human homologue, making animal model studies
problematic. Here we have produced P2X7 models and docked three structurally distinct inhibitors using
in silico approaches and show they have a similar mode of binding in which Phe95 plays a key role by
forming pi-stacking interactions. Importantly this residue is replaced by Leu in the rat P2X7 receptor
resulting in a signiﬁcantly reduced binding afﬁnity. This work provides new insights into binding of
P2X7 inhibitors and shows the structural difference in human and rat P2X7 receptors which results in
a difference in afﬁnity. Such information is useful both for the rational design of inhibitors based on these
scaffolds and also the way in which these compounds are tested in animal models.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).P2X receptors are a family of widely expressed ligand-gated,
calcium-permeable cationic channels which are solely activated
by extracellular adenosine triphosphate (ATP) in the body.1 The
seventh member of this family of receptors, P2X7, is expressed
primarily in cells of hemopoietic lineage such as macrophages,2
monocytes,3 lymphocytes,4 microglia5 and bone cells, and plays a
role in processes including inﬂammation,6 bone homeostasis7
and immunity.8 Whilst the normal activation of this channel is
necessary for these processes to occur, P2X7 has also been
implicated in playing a role in a wide range of diseases.9 The
altered expression and/or function of human P2X7 receptors has
been related to pathologies including chronic pain conditions,10,11
osteoporosis and bone fracture,12,13 rheumatoid arthritis,14
affective mood disorders15–17 and cancers18 including chronic
lymphocytic leukaemia.19 Because of the connection to these debil-
itating diseases and the appeal of ion channels as pharmaceutical
targets, these receptors have come under scrutiny as having poten-
tial for drug development. In vivo studies of P2X7 inhibitors in
rodents have shown great promise, and pharmacological inhibitionof this receptor has been demonstrated to attenuate neuropathic
and inﬂammatory pain,20 reduce inﬂammation in models of
rheumatoid arthritis21 and to be neuroprotective and to signiﬁ-
cantly reduce the number of amyloid plaques in the brain in mice
models of Alzheimer’s disease.22,23 As a result several P2X7 recep-
tor-speciﬁc compounds have been developed by pharmaceutical
companies to treat chronic conditions such as rheumatoid arthritis,
osteoarthritis and chronic obstructive pulmonary disease.24
However, despite much time and effort being invested in the
development of these compounds, the results in phase 1 and 2 clin-
ical trials25–28 have been disappointing. A deeper understanding of
the mode of binding of these inhibitors will aid in the development
of these potential drugs. An important consideration for the devel-
opment of these inhibitors must also be the structural differences
seen between rodent and human P2X7 receptors. This would cre-
ate problems when testing in an animal model situation unless
appropriate measures are made, for example, the generation of a
transgenic rat model. A thorough understanding of the P2X7 recep-
tor structure–function relationship is therefore crucial for the
development of P2X7 receptor ligands as therapeutics as well as
advancing our understanding of this receptor.
A major breakthrough in the understanding of the structure of
the P2X receptors arrived when the crystal structure of the zebra-
ﬁsh P2X4 receptor was solved.29 This structure gave an
Figure 1. Predicted antagonist binding site in relation to the known ATP binding
site. (A) Docking of SB203580 and ATP into the human P2X7 receptor, with residues
proximal to the antagonist binding site shown in purple. (B) Enlarged view of the
antagonist binding region highlighted in purple.
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closed state, which was followed by its structure in the ATP-bound
open state.30 This structure has guided homology modelling which
can be used as a basis for further in-depth structural studies of the
P2X7 receptor.
A number of P2X7-speciﬁc antagonists have been identiﬁed,
several of which display desirable drug-like properties. Many of
these display high levels of afﬁnity for the P2X7 receptor, acting
at concentrations in the low nanomolar range. These compounds
have the potential to act as a springboard for even more effective
antagonists. However, the opportunities for development are
somewhat limited. This is due in part to the lack of detailed knowl-
edge concerning the binding site of these antagonists. Whilst sev-
eral existing compounds are known to act as competitive
inhibitors, binding at the ATP binding pocket about which we
know a large amount, there are a number of non-competitive
P2X7-speciﬁc inhibitors. Where these compounds bind is less well
understood, and determining the site at which these compounds
interact with the receptor requires further investigation.Table 1







AZ11645373 31 nMTo this end we investigated the mode of binding of this family
of P2X7 antagonist inhibitors based on in silico approaches.
Structural models of P2X receptors were produced based on the
zebraﬁsh P2X4 crystal structure in the closed state (Protein Data
Bank code 4DW0) using Modeller version 9.1231,32 (Fig. 1A).
Docking studies were carried out using AutoDock version 4.2.33
All necessary ﬁles were prepared using AutoDock tools. The target
cavity ﬁle for each docking simulation consisted of a 15 Å sphere in
the extracellular domain of the P2X7 receptor, centred around the
amino acid at position 95, since this had previously been reported
to be involved in binding.34,35 Ligands were docked using standard
parameters and a standard Lamarckian genetic algorithm.
Dockings were visualised using AutoDock tools and were clustered
using 2 Å RMS. The most populated/lowest energy poses were
examined.
Three P2X7-speciﬁc inhibitors (Table 1) were docked into the
homology model of the human and rat P2X7 receptors (based on
the zebraﬁsh P2X4 receptor29) using AutoDock in order to investi-
gate potential binding sites of these compounds. 100 different
docking conformations were obtained for each compound with
the ten lowest predicted binding energy scores being selected for
further analysis.
Three commercially available and widely used P2X7-speciﬁc
antagonists were docked as part of this study; SB203580, KN62
and AZ11645373 (Table 1). The results of these molecular docking
simulations suggested a similar binding mode for each of the P2X7
antagonists. Figure 1 shows the general area at which all three
antagonists were predicted to act upon the receptor, which is prox-
imal to the ATP binding site. This pocket is located at the interface
between the neighbouring subunits, in close proximity to the a2
helix and two of the b-strands (b13 and b14) of the upper body
domain (Fig. 1B). This pocket is found in the inner vestibule of
the receptor and for the largest of the inhibitors, KN62, amino acids
from two different chains appear to interact with the inhibitor.
Residues within this region play a key role in determining the ori-
entation of the antagonists. Such residues which come intoIC50 at
rat
Activity in further species References
>30 lM None reported
>100 lM
Rhesus macaque monkey, IC50 86 nM Guinea pig, IC50
130 nM Dog, IC50 10 nM
42,43
>100 lM Rhesus macaque monkey, IC50 23 nM 42
Figure 2. Docking of SB203580, AZ11645373 and KN62 into the human (A, C and E)
and rat (B, D and F) P2X7 receptors, respectively. Residues Phe95 and Leu95 as well
as docked inhibitors are depicted in stick format. Residues labelled as A and B are
from different subunits of the same receptor.
3166 E. A. Caseley et al. / Bioorg. Med. Chem. Lett. 25 (2015) 3164–3167immediate contact with the docked antagonists include the
hydrophobic Phe95, Tyr295, Tyr299 and Tyr300 in addition to
the positively charged Lys297, which likely play an important role
in determining the orientation of bound antagonists such as those
docked in this study.
Of these important residues in the binding site, Phe95 appears
to have a key role in determining the orientation of each com-
pound. This residue is predicted to form pi-stacking interactions
with aromatic rings within the structures of the three antagonists
(Fig. 2A, C and E). Interestingly, previous studies have identiﬁedFigure 3. Sequence alignment of the ﬁrst 360 amino acids of the rat and human P2X7
highlighted in grey. Residues which differ between the two sequences are highlighted iPhe95 as determining the species-speciﬁc activity of some P2X7-
speciﬁc antagonists.34,35 This previous work investigated the
mechanism of action of species-speciﬁc P2X7 inhibitors. The ﬁrst
of these studies found that mutating Phe95 in the human receptor
to the Leu found in the rat greatly reduced the inhibitory activity of
KN62 and SB203580,34 whereas the second found that this was
also the case with AZ11645373.35 The three antagonists docked
in this study all display species-speciﬁc activity to varying degrees.
SB203580 acts as a low-afﬁnity, non-competitive inhibitor of the
human receptor, with an IC50 of approximately 5 lM, but does
not act at the rat receptor.36 KN62 inhibits the human receptor
with an IC50 of 100 nM but similarly does not act on the rat37
receptor. AZ11645373 inhibits human P2X7 with an IC50 of
90 nM whereas this compound is over 500-fold less effective at
inhibiting the rat receptor and results in less than 50% inhibition
at concentrations of 10 lM.38 In the rat P2X7 receptor the equiva-
lent residue to Phe95 is a leucine, which due to its lack of aromatic
side chain will lose the stacking interaction of these compounds
with the receptor. As such we carried out docking with these mole-
cules in the rat receptor to accompany the experiments in the
human P2X7 receptor. The results were strikingly different to those
seen in the human counterpart; with signiﬁcantly lower predicted
binding afﬁnities (in the millimolar range for the rat receptor com-
pared to nano- or micromolar range for human) as well as notably
different predicted binding positions within this site although ago-
nist efﬁcacy may also play a role.
As shown in Figure 2B, D and F, the pi-stacking interactions seen
between Phe95 and the aromatic rings of the inhibitors are lost in
the same site in the rat P2X7 receptor. This provides striking evi-
dence for the essential role of this residue in determining the spe-
cies-speciﬁc activity of these compounds. Sequence alignment of
residues within 8 Å of the predicted binding site shows that
Phe95 is the only residue which is not conserved between the
human and rat receptor located in a region which may interact
with the inhibitors (Fig. 3). The importance of this residue is fur-
ther validated by previous studies which used a human–rat chi-
meric receptor whereby a leucine replaced Phe at this position in
the human P2X7 receptor, greatly reducing the efﬁcacy of these
three inhibitors.34,35 Conversely, introducing the L95F mutation
into the rat receptor has been shown to have a varied impact on
the ability of the compounds described above to inhibit the rat
P2X7 receptor.34 SB203580 changes from having no effect at thereceptors with residues which are within 8 Å of the predicted ligand binding site
n green.
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tor, albeit to a lesser degree than the human receptor. Additionally,
the L95F mutation allows KN62 to modestly inhibit responses
when lower concentrations of ATP are applied.
The inhibitor binding site identiﬁed in these docking simula-
tions and importantly the mode of binding, builds on the previous
knowledge we have concerning the location at which these com-
pounds act, which is currently limited. This site is proximal to the
ATP binding site, buried within the receptor (Fig. 1). It has previ-
ously been shown that these antagonists are non-competitive inhi-
bitors and do not directly obstruct the ATP binding site.35,36,39
However, these compounds bind relatively closely to the ATP bind-
ing pocket. Studies combining molecular modelling simulations of
P2X receptors and experimental evidence have shown that ﬂexibil-
ity in this region is necessary for the activation of these receptors
following agonist binding.40,41 Inhibition of conformational ﬂexibil-
ity of the ATP binding pocket has been shown to result in depressed
responses to P2X receptor agonists,40 in addition to further evi-
dence which indicates that the tightening of the ATP-binding jaw
induces opening of the P2X channel.41 It has previously been sug-
gested that competitive P2X receptor antagonists prevent receptor
activation bymeans of preventing this movement of binding pocket
tightening.41 As such it seems reasonable to suggest that the bind-
ing of the antagonists examined in this study to a site behind the
ATP-binding pocket may inhibit channel activation by preventing
this vital conformational ﬂexibility of the P2X receptor.
The simulations carried out in this study highlight a potential
binding conformation for a series of P2X7-speciﬁc compounds
and provide new insights into existing studies. This is of great
interest in terms of drug development as the human P2X7 receptor
has been identiﬁed as a desirable target for therapeutic compounds
to treat the above-mentioned disease conditions. A more in-depth
understanding of the binding site of existing antagonists opens the
door for further rational development of these already effective
compounds as P2X7 receptor inhibitors.
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